Thu, Jul 31, 2014, 4:53 AM EDT - U.S. Markets open in 4 hrs 37 mins

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • bohemianclubman bohemianclubman Jan 18, 2013 10:32 AM Flag

    Great science from the home of the Nobel prize

    If Premacure was a public company it's shares would be on the move...... to the upside.

    Sometimes ROP causes blindness. Sometimes it doesn't.

    After many years of testing for safety, perfecting algorithms, and finally performing clinical trials, lead investigator Ann Hellstrom recently made some really strong statements. She didn't say that administration of Premiplex appears to help premature babies develop a less virulent case of ROP, she said - word for word, WE CAN PREVENT THE CONDITION. That is stunning, especially since the preemies that were administered Premiplex were in a group nearly 100% likely to develop the condition.

    But there is more. Premacure didn't simply inject the preemies with Premiplex. They developed algorithms based on body mass that allowed the company to "drip" Premiplex into the preemie, in order to match the amount of this growth protein that would be found in fully developed infants.

    Potentially, this method of administration could have far reaching ramifications for Insmed's dead and buried drug, iPLEX.

    When Celgene completed it's unsuccessful 300+ patient study injecting unbinded IGF1 in victims of ALS, dejected lead investigator Dr. Eric Sorenson made this comment: However, he added, "there is still a great deal of evidence that the IGF-1 pathway can be beneficial to people who have ALS, but just not the way we administered it."

    Not the way we administered it......... perhaps Premacure's administration method will unearth Insmeds dead and buried growth protein.

    Sentiment: Strong Buy

 
INSM
17.51+0.01(+0.06%)Jul 30 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.